9IP1.F Rocket Pharmaceuticals Inc

Healthcare Biotechnology Frankfurt Exchange
2.22 EUR
Close of Nov 12, 2026
1.77 4.67
Market cap
EUR 244M
P/E
-
P/B
0.72x
ROE
41.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 9IP1.F undervalued?

Graham number

The Graham number of Rocket Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Rocket Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Rocket Pharmaceuticals Inc yet.

Rocket Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakop…

Full company profile